The STArgardt Remofuscin Treatment Trial (STARTT): design and baseline characteristics of enrolled Stargardt patients Open Research Europe
Abstract Introduction Methods Results Discussion Funding Statement Data availability Underlying data Refere Abstract Background: This report describes the study design and baseline characteristics of patients with Stargardt disease (STGD1) enrolled in the STArgardt Remofuscin Treatment Trial (STARTT). Methods: In total, 87 patients with genetically confirmed STGD1 were randomized in a double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of 20 milligram oral remofuscin for 24 months. The primary outcome measure is change in mean quantitative autofluorescence value of an 8-segment ring centred on the fovea (qAF 8 ). Secondary efficacy variables are best corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), mesopic microperimetry (mMP), spectral domain optical coherence tomography (SD-OCT), reading speed on Radner reading charts, and patient-reported visual function as assessed by the National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25) and Functional Reading Independence (FRI) Index. Results: Mean age of participants was 35±11 years with 49 (56%) female. Median qAF 8 value was 438 Units (range 210-729). Median BCVA and LLVA in decimal units were 0.50 (range 0.13-0.80) and 0.20 (range 0.06-0.63), respectively. The median of the mean retinal sensitivity with mMP was 20.4 dB (range 0.0-28.8). SD-OCT showed median central subfield retinal thickness of 142 µm (range 72-265) and median macular volume of 1.65 mm 3 (range 1.13-2.19). Compared to persons without vision impairment,
both reading performance and patient-reported visual function were significantly lower (p<0.001, one sample t-test). Mean reading speed was 108±39 words/minute with logRAD-score of 0.45±0.28. Mean VFQ-25 composite score was 72±13. Mean FRI Index score 2.8±0.6. Conclusions: This trial design may serve as reference for future clinical trials as it explores the utility of qAF 8 as primary outcome measure. The baseline data represent the largest, multi-national, STGD1 cohort to date that underwent standardized qAF imaging, reading speed assessment and vision-related quality of life measures which all contribute to the characterization of STGD1. EudraCT registration: 2018-001496-20 (09/05/2019) Keywords: Stargardt disease, STGD1, ABCA4, Remofuscin, Soraprazan, qAF, quantitative autofluorescence
SHOW FULL ABSTRACT CITATION BIBTEX RIS
Patty PA Dhooge, Philipp T Möller, Camiel JF Boon et al.. The STArgardt Remofuscin Treatment Trial (STARTT): design and baseline characteristics of enrolled Stargardt patients. Open Research Europe. (2022). https://doi.org/10.12688/openreseurope.13872.3 Patty PA Dhooge, Philipp T Möller, Camiel JF Boon, Andrew J Lotery, Philipp Herrmann, Maurizio Battaglia Parodi, Wolfgang Klein, Mario G Fsadni, Thomas H Wheeler-Schilling, Oliver Jungmann, Hans Müller, Frank G Holz, Steffen Schmitz-Valckenberg, Tobias M Peters, Katarina Stingl, Carel B Hoyng, Victor Chong, Victor Chong, Patty Dhooge, Victor Chong, Patty Dhooge, Xiangrong Kong, Patty Dhooge
1Department of Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, 6500HB, The Netherlands 2Donders Institute for Brain, Cognition and Behaviour, Nijmegen, 6525EN, The Netherlands 3GRADE reading center, Bonn, 53127, Germany 4Department of Ophthalmology, University of Bonn, Bonn, 53127, Germany 5Department of Ophthalmology, Amsterdam University Medical Center, Amsterdam, 1081HV, The Netherlands 6Department of Ophthalmology, Leiden University Medical Center, Leiden, 2333ZA, The Netherlands 7Faculty of Medicine, University of Southampton, Southampton, SO17 1BJ, UK 8Center for Rare Diseases Bonn (ZSEB), University of Bonn, Bonn, 53113, Germany 9Department of Ophthalmology, Ospedale San Raffaele, Milan, 20132, Italy 10Katairo GmbH, Kusterdingen, 72127, Germany 11International Pharm-Med Ltd, Hemel Hempstead, HP1 1LD, UK 12University Eye Hospital, Center for Ophthalmology, Institute for Ophthalmic Research, University of Tübingen, Tübingen, 72076, Germany 13Smerud Medical Research Germany GmbH, Mannheim, D-68161, Germany 14John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, 84132, USA 15Center for Rare Eye Diseases, University of Tübingen, Tübingen, 72076, Germany 1Janssen R&D LLC, Raritan, NJ, USA 1Janssen R&D LLC, Raritan, NJ, USA 1197667, The Netherlands 1Janssen R&D LLC, Raritan, NJ, USA 1197667, The Netherlands 1School of Medicine, Johns Hopkins University, Baltimore, MD, USA 1197667, The Netherlands 